These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10785369)

  • 1. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3.
    Achen MG; Roufail S; Domagala T; Catimel B; Nice EC; Geleick DM; Murphy R; Scott AM; Caesar C; Makinen T; Alitalo K; Stacker SA
    Eur J Biochem; 2000 May; 267(9):2505-15. PubMed ID: 10785369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers.
    Stacker SA; Stenvers K; Caesar C; Vitali A; Domagala T; Nice E; Roufail S; Simpson RJ; Moritz R; Karpanen T; Alitalo K; Achen MG
    J Biol Chem; 1999 Nov; 274(45):32127-36. PubMed ID: 10542248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
    Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
    EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).
    Achen MG; Jeltsch M; Kukk E; Mäkinen T; Vitali A; Wilks AF; Alitalo K; Stacker SA
    Proc Natl Acad Sci U S A; 1998 Jan; 95(2):548-53. PubMed ID: 9435229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.
    Baldwin ME; Catimel B; Nice EC; Roufail S; Hall NE; Stenvers KL; Karkkainen MJ; Alitalo K; Stacker SA; Achen MG
    J Biol Chem; 2001 Jun; 276(22):19166-71. PubMed ID: 11279005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
    McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
    J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
    He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
    J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2.
    Kirkin V; Mazitschek R; Krishnan J; Steffen A; Waltenberger J; Pepper MS; Giannis A; Sleeman JP
    Eur J Biochem; 2001 Nov; 268(21):5530-40. PubMed ID: 11683876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.
    Paavonen K; Mandelin J; Partanen T; Jussila L; Li TF; Ristimaki A; Alitalo K; Konttinen YT
    J Rheumatol; 2002 Jan; 29(1):39-45. PubMed ID: 11824969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1.
    Wise LM; Veikkola T; Mercer AA; Savory LJ; Fleming SB; Caesar C; Vitali A; Makinen T; Alitalo K; Stacker SA
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3071-6. PubMed ID: 10077638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.
    Kukk E; Lymboussaki A; Taira S; Kaipainen A; Jeltsch M; Joukov V; Alitalo K
    Development; 1996 Dec; 122(12):3829-37. PubMed ID: 9012504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.
    Mäkinen T; Veikkola T; Mustjoki S; Karpanen T; Catimel B; Nice EC; Wise L; Mercer A; Kowalski H; Kerjaschki D; Stacker SA; Achen MG; Alitalo K
    EMBO J; 2001 Sep; 20(17):4762-73. PubMed ID: 11532940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro.
    Marconcini L; Marchio S; Morbidelli L; Cartocci E; Albini A; Ziche M; Bussolino F; Oliviero S
    Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9671-6. PubMed ID: 10449752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability.
    Stacker SA; Vitali A; Caesar C; Domagala T; Groenen LC; Nice E; Achen MG; Wilks AF
    J Biol Chem; 1999 Dec; 274(49):34884-92. PubMed ID: 10574962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
    Dias S; Hattori K; Heissig B; Zhu Z; Wu Y; Witte L; Hicklin DJ; Tateno M; Bohlen P; Moore MA; Rafii S
    Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10857-62. PubMed ID: 11553814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of VEGF-C and activation of its receptors VEGFR-2 and VEGFR-3 in trophoblast.
    Dunk C; Ahmed A
    Histol Histopathol; 2001 Apr; 16(2):359-75. PubMed ID: 11332691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo.
    Arbiser JL; Larsson H; Claesson-Welsh L; Bai X; LaMontagne K; Weiss SW; Soker S; Flynn E; Brown LF
    Am J Pathol; 2000 Apr; 156(4):1469-76. PubMed ID: 10751370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.